Company intelligence / Profile preview

Recovery Pharmaceuticals

Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Recovery Pharmaceuticals focused on developing small molecule drugs for addiction, with two pipeline programs: ATI-823 for tobacco use disorder and ATI-615 for cocaine-related disorders. No evidence of advanced clinical results; pipeline programs are listed as "Pending."

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Recovery Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recovery Pharmaceuticals.

Explore the full profile